Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant staphylokinase - Supergene

Next Previous
Drug Profile

Recombinant staphylokinase - Supergene

Alternative Names: Fortelyzin; Forteplase®; Gene modified staphylokinase - Supergene; Recombinant nonimmunogenic staphylokinase - Supergene; Recombinant staphylokinase variant - Supergene

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Supergene
  • Class Anti-ischaemics; Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ischaemic stroke; Peripheral arterial occlusive disorders; Pulmonary embolism
  • Phase II/III COVID 2019 infections
  • No development reported Myocardial infarction

Most Recent Events

  • 01 Jun 2025 Supergene initiates observational trials in Pulmonary embolism in Russia (IV) (NCT07245927)
  • 23 May 2024 Phase-III clinical trials in Pulmonary embolism in Russia (IV, Injection) (NCT06362746)
  • 12 Apr 2024 Supergene plans the FORPE-2 phase III trial for Pulmonary embolism in Russia (IV, Injection) in May 2024 (NCT06362746)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top